Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Assessing DDI Risk in the Digital Age

Posted on August 9th, 2017 by in Pharmacovigilance

pills pic for SD case study
In their 2012 Drug Regulations, the U.S. Food and Drug Administration recommended that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development.”

(more…)

The Link Between Big Pharma and the Supplement Industry

Posted on July 28th, 2017 by in Pharma R&D

When the FDA updated some of its guidelines around dietary supplements last year, many critics of the supplement (or “nutraceutical”) business were pleased to see a bit more regulation in an industry that enjoys surprisingly little oversight. (more…)

Maryland Attempts to Control Drug Prices

Posted on July 21st, 2017 by in Pharma R&D

Consumer concerns over the price of drugs remain high, so it’s not surprising that Maryland recently passed a bill aimed at controlling costs. (more…)

Biosimilars Development & its Future

Posted on July 10th, 2017 by in Pharma R&D

The pharmaceutical industry had really been quite optimistic as of late regarding regulatory overhaul and getting rid of the ever-present ‘red tape’ within the regulatory body in the US, and the FDA had shown a very positive response towards getting biosimilars approved. (more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7